← Trials/Trial dossier/NCT03574597

SELECT

CompletedPhase 3Results posted

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

833

Recruiting sites

—

Enrollment

17,604

actual

Study population

Cardiovascular disease, Obesity / overweight

Key I/E criteria

•BMI ≥27•Established CVD

Primary endpoint

•3-point MACE (Cardiovascular death, Non-fatal MI, Non-fatal stroke)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03574597

Org study IDEX9536-4388

Secondary ID2017-003380-35European Medicines Agency (EudraCT)

Secondary IDU1111-1200-5564World Health Organization (WHO)

Timeline

Milestones

Study first posted2018-07-02actual

Study start2018-10-24actual

Primary completion2023-06-21actual

Study completion2023-06-29actual

Last update posted2024-08-30actual

Results first posted2024-08-30actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Cardiovascular diseaseObesity / overweight

Eligibility

Who can enroll

Minimum age45 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial

•Male or female, age greater than or equal to 45 years at the time of signing informed consent

•Body mass index (BMI) greater than or equal to 27 kg/m^2

•Have established cardiovascular (CV) disease as evidenced by at least one of the following: prior myocardial infarction; prior stroke (ischemic or haemorrhagic stroke); or symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Exclusion criteria

Cardiovascular-related:

•Any of the following: myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within the past 60 days prior to the day of screening

•Planned coronary, carotid or peripheral artery revascularisation known on the day of screening

•Presently classified as being in New York Heart Association (NYHA) Class IV heart failure

Glycaemia-related:

•HbA1c greater than or equal to 48 mmol/mol (6.5 %) as measured by the central laboratory at screening

•History of type 1 or type 2 diabetes (history of gestational diabetes is allowed)

•Treatment with glucose-lowering agents within 90 days before screening

•Treatment with any glucagon-like-peptide-1 receptor agonist (GLP-1 RA) within 90 days before screening

General safety:

•History or presence of chronic pancreatitis

•Presence of acute pancreatitis within the past 180 days prior to the day of screening

•Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma

•End stage renal disease or chronic or intermittent haemodialysis or peritoneal dialysis

•Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed

•Severe psychiatric disorder which in the investigator's opinion could compromise compliance with the protocol

•Known or suspected hypersensitivity to trial products or related products

•Previous participation in this trial. Participation is defined as randomisation

•Receipt of any investigational medicinal product within 30 days before screening

•Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method

•Any disorder, unwillingness or inability, which in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol

Endpoints (58)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes

Cardiometabolic biomarkers

Glycemic / diabetes

Weight & body composition

Heart failure

Patient-reported / QoL

Renal / kidney

Cardiovascular outcomes

18 endpoints

Primary/registry result

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

3-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	569	—
Placebo	701	—

Hazard Ratio (HR)0.8095% CI0.72 – 0.89p< 0.0001Regression, Cox

Primary/protocol endpoint

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

3-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke

Secondary/registry result

Participants From Time of Randomisation to CV Death

Time frame:From randomisation (week 0) up to 240 weeks

Cardiovascular death

time to event, event

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	223	—
Placebo	262	—

Secondary/registry result

Participants From Time of Randomisation to All-cause Death

Time frame:From randomisation (week 0) up to 240 weeks

All-cause death

time to event, event

SNOMED 419620001

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	375	—
Placebo	458	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of an Expanded Composite CV Outcome Measure Consisting of: CV Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularisation or Unstable Angina Pectoris (UAP) Requiring Hospitalisation

Time frame:From randomisation (week 0) up to 240 weeks

Expanded / custom MACE composite

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	873	—
Placebo	1074	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

Expanded / custom MACE composite

time to event, event

componentsAll-cause death, Non-fatal MI, Non-fatal stroke

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	710	—
Placebo	877	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of Non-fatal MI

Time frame:From randomisation (week 0) up to 240 weeks

Non-fatal MI

time to event, event

SNOMED 22298006

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	234	—
Placebo	322	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

Non-fatal stroke

time to event, event

SNOMED 230690007

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	154	—
Placebo	165	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation

Time frame:From randomisation (week 0) up to 240 weeks

Coronary revascularization

time to event, event

SNOMED 415070008

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	473	—
Placebo	608	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation

Time frame:From randomisation (week 0) up to 240 weeks

Unstable angina hospitalization

time to event, event

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	109	—
Placebo	124	—

Secondary/protocol endpoint

Participants From Time of Randomisation to CV Death

Time frame:From randomisation (week 0) up to 240 weeks

Cardiovascular death

time to event, event

Secondary/protocol endpoint

Participants From Time of Randomisation to All-cause Death

Time frame:From randomisation (week 0) up to 240 weeks

All-cause death

time to event, event

SNOMED 419620001

Secondary/protocol endpoint

Time frame:From randomisation (week 0) up to 240 weeks

5-point MACE

time to event, event

componentsCardiovascular death, Non-fatal MI, Non-fatal stroke, Coronary revascularization, Unstable angina hospitalization

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

Expanded / custom MACE composite

time to event, event

componentsAll-cause death, Non-fatal MI, Non-fatal stroke

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of Non-fatal MI

Time frame:From randomisation (week 0) up to 240 weeks

Non-fatal MI

time to event, event

SNOMED 22298006

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke

Time frame:From randomisation (week 0) up to 240 weeks

Non-fatal stroke

time to event, event

SNOMED 230690007

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation

Time frame:From randomisation (week 0) up to 240 weeks

Coronary revascularization

time to event, event

SNOMED 415070008

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation

Time frame:From randomisation (week 0) up to 240 weeks

Unstable angina hospitalization

time to event, event

Weight & body composition

4 endpoints

Secondary/registry result

Change in Body Weight

Time frame:Week 0, week 104

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), percentage change in body weight	95% CI
Semaglutide	-9.39	—
Placebo	-0.87	—

Secondary/registry result

Change in Waist Circumference

Time frame:Week 0, week 104

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (mean), centimeter (cm)	95% CI
Semaglutide	-7.5	—
Placebo	-1.0	—

Secondary/protocol endpoint

Change in Body Weight

Time frame:Week 0, week 104

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change in Waist Circumference

Time frame:Week 0, week 104

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

10 endpoints

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%])

Time frame:From randomisation (week 0) up to 240 weeks

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	306	—
Placebo	1059	—

Secondary/registry result

Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%])

Time frame:From randomisation (week 0) up to 240 weeks

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	623	—
Placebo	1501	—

Secondary/registry result

Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%])

Time frame:At week 52, week 104

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (count_of_participants), Participants	95% CI
SemaglutideWeek 52	3363	—
Week 104	3271	—
PlaceboWeek 52	955	—
Week 104	978	—

Secondary/registry result

Change in HbA1c - Percentage

Time frame:Week 0, week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), Percentage of HbA1c	95% CI
Semaglutide	-0.31	—
Placebo	0.01	—

Secondary/registry result

Change in HbA1c - mmol/Mol

Time frame:Week 0, week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (mean), mmol/mol	95% CI
Semaglutide	-3.38	—
Placebo	0.10	—

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%])

Time frame:From randomisation (week 0) up to 240 weeks

HbA1c <6.5% achievement

time to event, event

LOINC 4548-4

Secondary/protocol endpoint

Participants From Time of Randomisation to HbA1c ≥ 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c <39 mmol/Mol [5.7%])

Time frame:From randomisation (week 0) up to 240 weeks

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Participants With HbA1c < 39 mmol/Mol (5.7%) (for Participants With a Screening HbA1c ≥ 39 mmol/Mol [5.7%])

Time frame:At week 52, week 104

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c - Percentage

Time frame:Week 0, week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c - mmol/Mol

Time frame:Week 0, week 104

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Heart failure

4 endpoints

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death

Time frame:From randomisation (week 0) up to 240 weeks

Expanded / custom MACE composite

time to event, event

componentsHeart-failure hospitalization, Urgent heart-failure visit, Cardiovascular death

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	300	—
Placebo	361	—

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit

Time frame:From randomisation (week 0) up to 240 weeks

Heart-failure composite

time to event, event

componentsHeart-failure hospitalization, Urgent heart-failure visit

SNOMED 84114007

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	97	—
Placebo	122	—

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death

Time frame:From randomisation (week 0) up to 240 weeks

Expanded / custom MACE composite

time to event, event

componentsHeart-failure hospitalization, Urgent heart-failure visit, Cardiovascular death

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit

Time frame:From randomisation (week 0) up to 240 weeks

Heart-failure composite

time to event, event

componentsHeart-failure hospitalization, Urgent heart-failure visit

SNOMED 84114007

Renal / kidney

2 endpoints

Secondary/registry result

Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure

Time frame:From randomisation (week 0) up to 240 weeks

5-point renal composite

time to event, event

componentsuACR, change, eGFR, change, End-stage renal disease, Kidney-replacement therapy, Renal death

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide	155	—
Placebo	198	—

Secondary/protocol endpoint

Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure

Time frame:From randomisation (week 0) up to 240 weeks

5-point renal composite

time to event, event

componentsuACR, change, eGFR, change, End-stage renal disease, Kidney-replacement therapy, Renal death

Cardiometabolic biomarkers

16 endpoints

Secondary/registry result

Change in Systolic Blood Pressure (SBP)

Time frame:Week 0, week 104

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (mean), Millimetre of mercury (mmHg)	95% CI
Semaglutide	-3.8	—
Placebo	-0.6	—

Secondary/registry result

Change in Diastolic Blood Pressure (DBP)

Time frame:Week 0, week 104

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (mean), mmHg	95% CI
Semaglutide	-1.1	—
Placebo	-0.4	—

Secondary/registry result

Change in Pulse

Time frame:Week 0, week 104

Heart rate, change

change from baseline, improvement

Posted result

Group	Value (mean), beats per mintue (bpm)	95% CI
Semaglutide	3.8	—
Placebo	0.9	—

Secondary/registry result

Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

Time frame:Week 0, week 104

hs-CRP, change

ratio, improvement

LOINC 30522-7

Posted result

Group	Value (geometric_mean), ratio of hsCRP	95% CI
Semaglutide	0.61	—
Placebo	1.00	—

Secondary/registry result

Change in Total Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Posted result

Group	Value (geometric_mean), ratio of total cholesterol	95% CI
Semaglutide	0.95	—
Placebo	0.98	—

Secondary/registry result

Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

HDL-C, change

ratio, improvement

LOINC 2085-9

Posted result

Group	Value (geometric_mean), ratio of HDL	95% CI
Semaglutide	1.05	—
Placebo	1.01	—

Secondary/registry result

Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

LDL-C, change

ratio, improvement

LOINC 13457-7

Posted result

Group	Value (geometric_mean), ratio of LDL	95% CI
Semaglutide	0.95	—
Placebo	0.97	—

Secondary/registry result

Change in Triglycerides - Ratio to Baseline

Time frame:Week 0, week 104

Triglycerides, change

ratio, improvement

LOINC 2571-8

Posted result

Group	Value (geometric_mean), ratio of triglycerides	95% CI
Semaglutide	0.82	—
Placebo	0.97	—

Secondary/protocol endpoint

Change in Systolic Blood Pressure (SBP)

Time frame:Week 0, week 104

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in Diastolic Blood Pressure (DBP)

Time frame:Week 0, week 104

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Secondary/protocol endpoint

Change in Pulse

Time frame:Week 0, week 104

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint

Change in High Sensitivity C-Reactive Protein (hsCRP) - Ratio to Baseline

Time frame:Week 0, week 104

hs-CRP, change

ratio, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change in Total Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High Density Lipoprotein (HDL) Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low Density Lipoprotein (LDL) Cholesterol - Ratio to Baseline

Time frame:Week 0, week 104

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in Triglycerides - Ratio to Baseline

Time frame:Week 0, week 104

Triglycerides, change

ratio, improvement

LOINC 2571-8

Patient-reported / QoL

4 endpoints

Secondary/registry result

Change From Randomisation (Week 0) in Participant Reported Outcome (PRO): EuroQol Five Dimensions Five Level Questionnaire (EQ-5D-5L) Index Score to Week 104

Time frame:Week 0, week 104

EQ-5D index

change from baseline, improvement

Posted result

Group	Value (mean), score on a scale	95% CI
Semaglutide	0.01	—
Placebo	-0.01	—

Secondary/registry result

Change From Randomisation (Week 0) in PRO: EuroQol Five Dimensions Visual Analogue Scale (EQ-5D-VAS) to Week 104

Time frame:Week 0, week 104

EQ-5D VAS

change from baseline, improvement

Posted result

Group	Value (mean), score on a scale	95% CI
Semaglutide	2.38	—
Placebo	0.77	—

Secondary/protocol endpoint

Change From Randomisation (Week 0) in Participant Reported Outcome (PRO): EuroQol Five Dimensions Five Level Questionnaire (EQ-5D-5L) Index Score to Week 104

Time frame:Week 0, week 104

EQ-5D index

change from baseline, improvement

Secondary/protocol endpoint

Change From Randomisation (Week 0) in PRO: EuroQol Five Dimensions Visual Analogue Scale (EQ-5D-VAS) to Week 104

Time frame:Week 0, week 104

EQ-5D VAS

change from baseline, improvement

Publications (22)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Canonical study publications

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
canonical
The New England journal of medicine2023 Dec 14PMID37952131doi:10.1056/NEJMoa2307563via CT.gov reference + pubmed nct search
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
canonical
American heart journal2020 Nov (month)PMID32916609doi:10.1016/j.ahj.2020.07.008via CT.gov reference

Registry references + supporting bibliography

Calculating cost per event avoided using a composite number needed to treat.
Journal of medical economics2026 Dec (month)PMID41562647doi:10.1080/13696998.2026.2615606via pubmed nct search
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Nature medicine2026 Apr 2PMID41928037doi:10.1038/s41591-026-04281-1via clinicaltrials gov reference derived + pubmed nct search
Prevalence and Associations of Systemic Inflammation in Heart Failure Across the Spectrum of Ejection Fraction.
JACC. Heart failure2026 Feb (month)PMID41099689doi:10.1016/j.jchf.2025.102712via pubmed nct search
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical Trial.
JAMA cardiology2026 Feb 1PMID41433034doi:10.1001/jamacardio.2025.4824via clinicaltrials gov reference derived + pubmed nct search
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
Journal of medical economics2025 Dec (month)PMID39882599doi:10.1080/13696998.2025.2459529via clinicaltrials gov reference derived + pubmed nct search
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Lancet (London, England)2025 Nov 8PMID41138739doi:10.1016/S0140-6736(25)01375-3via clinicaltrials gov reference derived + pubmed nct search
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
Advances in therapy2025 May (month)PMID40156748doi:10.1007/s12325-025-03176-wvia clinicaltrials gov reference derived + pubmed nct search
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials.
Clinical journal of the American Society of Nephrology : CJASN2025 Feb 1PMID39480988doi:10.2215/CJN.0000000584via clinicaltrials gov reference derived + pubmed nct search
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
The lancet. Diabetes & endocrinology2025 Jan (month)PMID39608381doi:10.1016/S2213-8587(24)00271-7via clinicaltrials gov reference derived + pubmed nct search
The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.
Journal of the American College of Cardiology2024 Oct 22PMID39217559doi:10.1016/j.jacc.2024.08.007via clinicaltrials gov reference derived + pubmed nct search
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Lancet (London, England)2024 Sep 7PMID39222642doi:10.1016/S0140-6736(24)01643-Xvia clinicaltrials gov reference derived + pubmed nct search
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Lancet (London, England)2024 Aug 24PMID39181597doi:10.1016/S0140-6736(24)01498-3via clinicaltrials gov reference derived + pubmed nct search
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Nature medicine2024 Jul (month)PMID38796653doi:10.1038/s41591-024-03015-5via clinicaltrials gov reference derived + pubmed nct search
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Nature medicine2024 Jul (month)PMID38740993doi:10.1038/s41591-024-02996-7via clinicaltrials gov reference derived + pubmed nct search
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
American journal of preventive cardiology2023 Jun (month)PMID37313358doi:10.1016/j.ajpc.2023.100502via pubmed nct search
Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease.
Hepatology (Baltimore, Md.)2023 Jun 1PMID36738088doi:10.1097/HEP.0000000000000327via clinicaltrials gov reference derived + pubmed nct search
Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta-analysis of placebo-controlled randomized trials.
Diabetes, obesity & metabolism2022 Aug (month)PMID35373878doi:10.1111/dom.14707via clinicaltrials gov reference derived + pubmed nct search
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.
Current opinion in cardiology2022 Jul 1PMID35175229doi:10.1097/HCO.0000000000000955via clinicaltrials gov reference derived + pubmed nct search
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
The Cochrane database of systematic reviews2021 Oct 25PMID34693515doi:10.1002/14651858.CD013650.pub2via clinicaltrials gov reference derived + pubmed nct search
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine2021 Mar 18PMID33567185doi:10.1056/NEJMoa2032183via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.